Briefing
Personalized, ctDNA analysis to detect minimal residual disease and identify patients at high risk of relapse with multiple myeloma.
ctDNA was detectable in 17/24 (70.8%) before transplant, 15/28 (53.6%) at about 3 months after transplant, and 11/28 (39.2%) during later surveillance. Of 15 patients MRD-positive at 3 months, 14 (93.3%) later relapsed (HR 5.64, 95% CI 1.8-17, P=0.0003). Median PFS was 84 months if ctDNA-negative at 3 months vs 31 months if positive (P=0.003). The 3-month positive predictive value for relapse was 93.3%, higher than marrow flow cytometry (68.4%) in this series.
- n: 28 patients after upfront autologous transplant; 80 plasma timepoints; median follow-up 92.4 months; single-center retrospective
- Assay: Signatera (personalized tumor-informed mPCR-NGS), assessed about 3 months after transplant; bone-marrow comparison used multiparameter flow cytometry at 10^-4